Diets in Oncology

WHY THIS LOCATION IN PARTICULAR

NCI states explicitly that nutrition complications are usually most notable and severe with tumors involving the digestive tract or head and neck, owing to mechanical obstruction or dysfunction ^[1]. For this location NCI lists dysphagia and odynophagia, xerostomia and taste changes as typical consequences, and for radiotherapy of the head and neck region — xerostomia, mucositis and taste changes, with thick saliva as a later effect ^[1].

THE SCALE OF THE PROBLEM

A systematic review published in 2026, covering 31 studies, reports that malnutrition affects 30–50% of patients at diagnosis and up to 90% during therapy ^[2]. This is why nutritional status is treated here as part of the treatment plan rather than a side issue: malnutrition directly affects whether the planned radiotherapy or chemoradiotherapy can be delivered without interruption.

WHAT THE EVIDENCE SAYS ABOUT EACH FORM OF SUPPORT. The same review compares three approaches ^[2]:

• oral nutritional supplements — early use was associated with fewer treatment interruptions, particularly before escalation to enteral feeding;
• prophylactic percutaneous endoscopic gastrostomy — associated with reduced weight loss, fewer unplanned hospitalisations and higher treatment completion rates, although the authors explicitly caution that these findings must be interpreted carefully because the available evidence is observational;
• nasogastric tube feeding — associated with fewer device-related complications and lower long-term dependence, but heterogeneity across studies and the predominance of gastrostomy-focused evidence prevented direct comparison.

WHAT THE EVIDENCE DOES NOT SETTLE

The review authors put it plainly: comparative evidence remains insufficient to define the optimal enteral approach, and mucositis, dysphagia and impaired oral intake remained the most significant outcomes DESPITE the implementation of multiple nutritional support measures ^[2]. In other words, nutritional support mitigates the consequences of treatment but does not remove them, and the choice between gastrostomy and nasogastric tube has no randomised-trial answer today. High-quality randomised trials integrating oral health-related outcomes are needed ^[2].

STRENGTH OF EVIDENCE

Moderate. In favour: the data come from a systematic review conducted in accordance with PRISMA, with methodological quality appraisal of the included studies, and the malnutrition figures are consistent and high ^[2]. Against full certainty: the key observations on the benefit of prophylactic gastrostomy come from observational studies rather than randomisation, and are described as such by the authors ^[2].

WHAT THIS ENTRY DOES NOT SAY

It does not indicate which method of feeding any individual patient should choose, or when a gastrostomy should be placed. That decision is made by the treating team — radiation oncologist, head and neck surgeon, clinical dietitian and speech and language therapist — on the basis of nutritional status, the radiotherapy plan and symptom severity. The service does not interpret individual clinical situations.

Sources

1. [1] National Cancer Institute — PDQ: Nutrition in Cancer Care (Health Professional Version): cancer.gov ↗
2. [2] Nutritional management and oral health-related outcomes in head and neck cancer treated with radiotherapy or chemoradiotherapy: a systematic review, BMC Oral Health 2026 (PMID 42010533): pubmed.ncbi.nlm.nih.gov ↗

WHAT ORAL NUTRITIONAL SUPPLEMENTS ARE

They are ready-made liquid or powdered products registered as foods for special medical purposes. In a small volume they provide concentrated energy, protein, fat and carbohydrate, and often fibre, vitamins and minerals. NCI stresses that they are not intended to serve as the sole source of nutrition — they supplement what the patient eats ^[1].

WHAT THE EVIDENCE SHOWS

The strength of evidence is moderate and concerns nutritional indicators rather than survival.

• Multinutrient, high-protein supplements significantly improved total energy and protein intake and reduced the incidence of complications ^[1].
• In head and neck cancer treated with radiotherapy or chemoradiotherapy, early use of supplements was associated with fewer treatment interruptions, particularly before escalation to tube feeding; the review authors note that comparative data remain too limited to define the optimal approach ^[2].
• In perioperative care (a review of patients undergoing prostate cancer surgery), supplements form part of the recommended pathway alongside early screening for malnutrition ^[3].
• A review of 38 studies found NO benefit from fish-oil-enriched supplements in the treatment of cachexia in advanced cancer ^[1].

WHAT SUPPLEMENTS DO NOT SOLVE

A supplement will not by itself halt progressive cancer cachexia, nor replace treatment of the cause of appetite loss. It is not an anticancer drug and there are no data showing an effect on the outcome of cancer treatment.

A PRACTICAL LIMITATION PATIENTS THEMSELVES RAISE

A review of patient experiences after colorectal surgery found that experiences with oral nutritional supplements vary widely, and that palatability largely determines whether they are consumed ^[4]. This is not a minor detail: a supplement that is not drunk does not nourish, and unacceptable taste is a common reason for abandoning advice.

WHERE TO SEEK HELP

Choosing a supplement (energy density, protein content, form, fibre content, suitability in diabetes or renal impairment) is the responsibility of the treating physician and a clinical dietitian. This site does not give dietary advice and does not recommend specific products.

Sources

1. [1] National Cancer Institute — Nutrition in Cancer Care (PDQ), Health Professional Version (oral nutrition supplements; multinutrient high-protein products; systematic review of 38 studies on fish oil in cachexia): cancer.gov ↗
2. [2] Nutritional management and oral health-related outcomes in head and neck cancer treated with radiotherapy or chemoradiotherapy: a systematic review. BMC Oral Health 2026 (PMC13267656): europepmc.org ↗
3. [3] Evidence-based perioperative nutritional management for patients undergoing prostate cancer surgery: a systematic review. Gland Surgery 2026 (PMC13264766): europepmc.org ↗
4. [4] Patient Experiences of Nutrition in Enhanced Recovery After Colorectal Surgery: A Systematic Review. Nutrients 2026 (PMC13258613): europepmc.org ↗

WHY THIS LOCATION IN PARTICULAR

NCI states explicitly that nutrition complications are usually most notable and severe with tumors involving the digestive tract or head and neck, owing to mechanical obstruction or dysfunction ^[1]. For the oesophagus and stomach NCI lists dysphagia and odynophagia as typical consequences, and describes tumour-induced weight loss as occurring frequently in solid tumours of the lung, pancreas and upper gastrointestinal tract, and less often in breast cancer or lower gastrointestinal cancer ^[1]. Surgery adds a further mechanism: NCI notes that procedures including oesophagectomy and gastrectomy may produce early satiety, a premature feeling of fullness ^[1].

THE SCALE OF THE PROBLEM AFTER CHEMORADIOTHERAPY

A secondary analysis of a prospective cohort of 260 patients with oesophageal squamous cell carcinoma treated with concurrent chemoradiotherapy between 2008 and 2024 found that cachexia developed after treatment in 60.7% of patients ^[2]. Independent predictors of cachexia were greater tumour length and a larger tumour-occupying proportion of the lumen, with cut-offs of at least 6 cm in length and at least 70% of the luminal area ^[2].

PRETREATMENT FEEDING STOMA — WHO ACTUALLY BENEFITED. This is the crux of the topic and the part most often oversimplified. Across the cohort as a whole, creating a gastrostomy or jejunostomy before chemoradiotherapy was NOT associated with longer progression-free or overall survival ^[2]. Benefit appeared only in the subgroup whose tumour occupied at least 70% of the lumen: less cachexia, better treatment response (odds ratio 2.78; P=0.028), longer median progression-free survival (6 vs 4 months; P=0.012) and longer median overall survival (11 vs 9 months; P=0.009) ^[2]. In patients with a smaller tumour-occupying proportion no benefit was found ^[2]. The authors draw a cautious conclusion: the tumour-occupying proportion may serve as a selection criterion for this invasive procedure, rather than as an argument for performing it in everyone ^[2].

STRENGTH OF EVIDENCE

Limited. In favour: the data come from a large, prospectively collected cohort with long follow-up, and tumour measurements were taken from standardised endoscopic images ^[2]; the statements on nutritional mechanisms and on early satiety after surgery rest on NCI's review ^[1]. Against full certainty: the key finding on feeding stomas comes from a SUBGROUP ANALYSIS of a non-randomised study — treating clinicians decided who received a stoma, so differences between groups may partly reflect that choice. The study concerns squamous cell carcinoma; evidence of comparable strength for oesophageal adenocarcinoma is lacking.

WHAT THIS ENTRY DOES NOT SAY

It does not indicate whether any individual patient should have a gastrostomy or jejunostomy, when, or in what form. That decision is made by the treating team — medical oncologist, radiation oncologist, surgeon and clinical dietitian — on the basis of endoscopic findings, nutritional status and the treatment plan. The service does not interpret individual clinical situations or test results.

Sources

1. [1] National Cancer Institute — PDQ: Nutrition in Cancer Care (Health Professional Version): cancer.gov ↗
2. [2] Pretreatment feeding-stoma placement in advanced esophageal cancer: defining optimal patient selection criteria. Esophagus 2026 (PMID 42165951, PMC13319426): europepmc.org ↗

WHAT IT IS

Enteral nutrition means delivering a prepared nutrient formula directly into the stomach or intestine through a tube — a narrow catheter passed through the nose or through the abdominal wall. Parenteral nutrition means delivering nutrients intravenously, bypassing the digestive tract altogether. Both serve the same purpose: meeting the needs of a patient who cannot meet them by eating.

WHEN IT IS CONSIDERED AT ALL

The National Cancer Institute PDQ summary ties nutrition support to the situation of a patient who is malnourished and unable, for a prolonged period, to take in adequate nutrients by mouth ^[1]. It is therefore not a dietary top-up "for strength", but a response to a specific, ongoing problem with food intake.

WHY THE ENTERAL ROUTE COMES FIRST

PDQ states the principle plainly: if the patient has a functioning gastrointestinal tract, enteral nutrition is the route used ^[1]. Feeding through the gut keeps it working and avoids the complications associated with central venous access. Parenteral nutrition is reserved for situations in which the gut does not work or is obstructed.

HAEMATOPOIETIC CELL TRANSPLANTATION — THE ONE EXPLICIT TIME THRESHOLD. For patients undergoing haematopoietic cell transplantation, PDQ gives a concrete criterion: nutrition support is given to those who are malnourished and expected to be unable to ingest or absorb adequate nutrients for a prolonged period, defined as more than 7-14 days ^[1]. This is the only figure the source states in this context, and it applies only to this group of patients.

WHAT IT DOES NOT SOLVE

Nutrition support is not a cancer treatment and does not replace anticancer therapy. PDQ presents no evidence for routinely adding it to standard chemotherapy or radiotherapy in patients who are eating adequately; for that period it puts symptom control and practical coping strategies first ^[1].

WHAT IS OUTSIDE THE SCOPE OF THIS PAGE

Detailed starting thresholds, choice of formula, rate of delivery and prevention of refeeding complications are matters for clinical guidelines and individual assessment — they belong to the treating team and the responsible physician, not to an information page. This page describes what these methods are and the logic by which they are ordered, not when any particular person should use them.

SOURCES.

• ^[1] National Cancer Institute, PDQ Nutrition in Cancer Care (health professional version)

Sources

1. National Cancer Institute — PDQ Nutrition in Cancer Care (health professional version): cancer.gov ↗

WHY THIS ENTRY EXISTS

Throughout this service the message recurs that malnutrition in cancer must not be dismissed. This page addresses the other side of the same problem: bringing someone out of prolonged starvation is a separate medical task, and haste in it can be more dangerous than the deficit itself. It is one of the few situations in clinical nutrition where faster does not mean better.

WHAT THE PHENOMENON IS

During prolonged starvation the body switches to burning fat, and stores of phosphate, potassium and magnesium become depleted — even though their blood concentrations may appear normal ^[3]. When feeding resumes, rising glucose stimulates insulin secretion, and insulin drives phosphate, potassium and magnesium from the blood into cells; at the same time increased glucose metabolism consumes thiamine (vitamin B1) stores ^[3]. The classic laboratory feature is a fall in phosphate, but the picture also includes disturbed sodium and fluid balance and deficiency of thiamine, potassium and magnesium ^[1][2].

WHY IT MATTERS

The reported consequences can be severe and affect several systems at once ^[3]:

• heart — arrhythmias, low blood pressure, in extreme cases cardiac arrest;
• respiratory system — respiratory failure, pulmonary oedema;
• nervous system — features of thiamine deficiency (confusion, memory impairment, disturbed balance and eye movements).

For this reason, feeding is restarted under laboratory monitoring rather than by impression.

WHOM IT CONCERNS IN ONCOLOGY

The risk relates not to the diagnosis itself but to the DURATION AND DEPTH of reduced intake ^[1]. In oncological practice this usually means situations in which eating has been physically difficult or impossible for weeks: narrowing of the oesophagus or stomach, bowel obstruction, severe dysphagia after treatment of head and neck cancer, intractable vomiting, and advanced cancer cachexia. Additional risk factors include low body mass index, unintentional weight loss, previous starvation, past alcohol misuse and low baseline electrolyte levels ^[3].

WHAT THE TREATING TEAM DOES

The ESPEN guideline describes increasing nutritional provision slowly over several days and supplying vitamin B1 together with a balanced micronutrient mixture before and during repletion; potassium, phosphate and magnesium are monitored and replaced as needed ^[1][2]. We deliberately give NO doses or threshold values here — these are set individually from body weight, laboratory results and route of administration, and quoting them outside the clinical context would amount to advice for an individual rather than a description of knowledge.

HOW STRONG IS THE EVIDENCE

The ESPEN recommendation to advance nutrition slowly carries a strong grade but rests on a LOW level of evidence and on expert consensus ^[1][2]. The mechanism is well described physiologically and clinically ^[3], whereas trials comparing different refeeding schedules are few — which is why we tagged this entry as based on limited evidence. That does not mean the hazard is doubtful; it means there is no single schedule proven in trials.

WHAT THIS ENTRY DOES NOT SAY

It does not say after how many days without eating the risk appears in a given person, nor how many calories may be given on the first day. Nor is it a reason to postpone nutritional treatment — on the contrary: malnutrition in cancer requires treatment, and knowledge of refeeding syndrome exists so that it can be treated safely.

THE DECISION BELONGS TO THE DOCTOR

Whether a person is at risk of refeeding syndrome, and how fast to advance feeding, is decided by the treating specialist together with the nutrition team. If a patient has eaten very little for a prolonged period, it is worth telling the treating team BEFORE intensive refeeding begins — including when it takes place at home with oral nutritional supplements.

Sources

1. [1] Muscaritoli M i wsp. — ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr 2021;40(5):2898-2913 (PMID 33946039) — zalecenie powolnego, rozłożonego na kilka dni zwiększania żywienia po długotrwale zmniejszonym przyjmowaniu pokarmu; siła zalecenia wysoka, poziom dowodów niski (konsensus): pubmed.ncbi.nlm.nih.gov ↗
2. [2] ESPEN — ESPEN practical guideline: Clinical Nutrition in cancer (pełny tekst wytycznych, espen.org) — hipofosfatemia jako klasyczna cecha zespołu; profilaktyczna podaż witaminy B1 i mieszanki mikroelementów; monitorowanie potasu, fosforanów i magnezu: espen.org ↗
3. [3] Persaud-Sharma D, Saha S, Trippensee AW — Refeeding Syndrome. StatPearls, NCBI Bookshelf (NBK564513) — definicja, mechanizm (wyrzut insuliny, przesunięcie fosforanów/potasu/magnezu do komórek, zużycie tiaminy), czynniki ryzyka i następstwa sercowe, oddechowe i neurologiczne: ncbi.nlm.nih.gov ↗

WHY IT IS DONE

Quoting the NCI: extra protein and calories help keep your strength up to deal with the side effects of treatment, prevent malnutrition and maintain the best possible quality of life ^[1]. The second argument is purely practical and often underrated: staying nourished increases the chance of receiving treatment without unplanned breaks — and interruptions to chemotherapy or radiotherapy carry a cost.

WHAT IS ADVISED IN PRACTICE

The NCI's advice during treatment runs counter to popular notions of an "anticancer diet": meals rich in protein and calories, smaller portions more often (around five to six a day rather than three large ones), adapting food to the taste and smell changes that commonly accompany treatment, and food safety precautions while immunity is weakened ^[1]. Menu planning belongs to a registered dietitian within the treating team ^[1].

CANCER CACHEXIA

This is not the same as poor appetite. The NCI describes it as a wasting syndrome causing weakness, weight loss and loss of fat and muscle, which can occur even when a person is eating well ^[1]. The implication matters: simply eating more does not reverse cachexia, and its diagnosis and management belong to the treating team rather than to self-directed attempts.

WHEN EATING IS NOT ENOUGH

Artificial nutrition support (delivery through a feeding tube, or intravenously when the gastrointestinal tract cannot be used) is an option for people who cannot eat or digest enough food to stay nourished ^[1]. This is a clinical decision, made individually and depending on the situation, including tumour type and planned treatment ^[1].

WHAT THIS ENTRY DOES NOT CONTAIN

We do not give protein or calorie requirements per kilogram of body weight, although such figures appear in nutrition society guidelines — we could not confirm them in the source available to us, and an unverified number is worse than none. Requirements are set individually by a clinical dietitian ^[1].

Sources

1. National Cancer Institute — Nutrition During Cancer Treatment, PDQ 2024: cancer.gov ↗

WHAT IT IS

An international expert panel (Lancet Oncology, 2011) defined cancer cachexia as a multifactorial syndrome of ongoing loss of skeletal muscle mass — with or without loss of fat mass — that CANNOT be fully reversed by conventional nutritional support and leads to progressive functional impairment ^[1]. It is driven by a negative protein and energy balance arising from a variable combination of reduced food intake and abnormal metabolism ^[1]. That last part is the key to this entry: cachexia is not simply undereating. The National Cancer Institute puts it plainly: wasting "can occur even when you are eating well" ^[4].

HOW IT IS DIAGNOSED

The agreed criterion is weight loss greater than 5%, or greater than 2% in people already depleted by body-mass index (below 20 kg/m²) or by skeletal muscle mass (sarcopenia) ^[1]. The consensus describes stages — precachexia, cachexia and refractory cachexia — and states that assessment should cover four domains: anorexia or reduced food intake, catabolic drive, muscle mass and strength, and functional and psychosocial impairment ^[1].

HOW COMMON, AND HOW OFTEN MISSED. A retrospective record analysis of 76 547 cancer patients (Journal of Cachexia, Sarcopenia and Muscle, 2026) found cachexia in 2.42% of the whole cohort but in 29.3% of 6946 patients with colorectal, pancreatic or bronchial/lung cancer ^[2]. What matters most is what the authors found inside the records themselves: ICD coding identified 620 patients and free-text analysis a further 1507; in addition, 1340 patients had a BMI below 20 or more than 5% weight loss yet were not coded as cachectic ^[2]. The authors conclude that standard coding substantially underestimates the prevalence of cachexia ^[2].

WHY IT MATTERS TO THE PATIENT

A systematic review of 37 studies covering 52 053 patients with solid tumours (Journal of Cachexia, Sarcopenia and Muscle, 2026) found cachexia associated with worse physical function (a statistically significant association in 25 of 31 studies, 80.6%), worse health-related quality of life (22 of 24, 91.7%), worse performance status (14 of 16, 87.5%) and worse activities of daily living (6 of 6) ^[3]. The same review exposed a real limitation of the literature: eleven different definitions of cachexia were used, and the 2011 consensus criteria in only 45% of studies, so comparisons between studies carry uncertainty ^[3].

THE SCOPE OF WHAT WE WRITE HERE

We deliberately do NOT give calorie targets, grams of protein per kilogram, or enteral and parenteral feeding regimens. Those decisions belong to the treating team and clinical dietitian, because they depend on the diagnosis, the stage of treatment, gut function and comorbidities. Nor do we know of — and we did not find in reference-class sources — any diet or supplement that can honestly be said to reverse cachexia; the consensus definition itself states that conventional nutritional support does not ^[1]. Offers of "anti-wasting diets" and muscle-rebuilding preparations therefore call for particular caution: a promise that the best-documented nutritional intervention does not keep will not be kept by a product sold without such documentation.

WHAT FOLLOWS IN PRACTICE

Early recognition matters, because the consensus describes a precachexia stage preceding the full syndrome ^[1]. Weight loss is measurable and worth recording — the record-based data show it is often present in measurements yet never reaches the diagnosis ^[2]. Raising unintended weight loss with the treating team is therefore reasonable even when the patient "is eating normally" ^[4].

Sources

1. Fearon K i wsp. — Definition and classification of cancer cachexia: an international consensus, The Lancet Oncology 2011: europepmc.org ↗
2. Colardelle Y i wsp. — Cancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital, Journal of Cachexia, Sarcopenia and Muscle 2026: europepmc.org ↗
3. Crawford J i wsp. — Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review, Journal of Cachexia, Sarcopenia and Muscle 2026: europepmc.org ↗
4. National Cancer Institute — Nutrition During Cancer Treatment, cancer.gov 2024: cancer.gov ↗

WHAT THIS ENTRY COVERS

This is about nutritional management delivered by the treating team around planned cancer surgery, especially of the gastrointestinal tract. It comprises three distinct things that should not be conflated: assessment of nutritional risk before surgery, shortening the fasting period and returning to oral intake early after surgery, and so-called immunonutrition formulas (enriched with arginine, omega-3 fatty acids and nucleotides, among others). The first two are part of standard perioperative care; the third is an add-on intervention, and it is the subject of most of the studies cited here.

WHAT THE EVIDENCE SHOWS

An umbrella review of 54 meta-analyses in patients undergoing cancer surgery (BMC Cancer, 2026) reported, in favour of immunonutrition:

• overall complications RR 0.79 (95% CI 0.70–0.88)
• infectious complications RR 0.61 (0.58–0.65)
• surgical-site infection RR 0.66 (0.59–0.74)
• mortality HR 0.86 (0.74–0.99)
• length of hospital stay shorter by a mean of 1.75 days (–2.09 to –1.41)

The ESPEN guideline on clinical nutrition in surgery (2025 update) states the general principles: start nutritional therapy as soon as nutritional risk becomes apparent, avoid long periods of preoperative fasting, and re-establish oral feeding, the preferred route, as early as possible after surgery.

WHERE THE SOURCES DIVERGE — AND WHY WE SAY SO PLAINLY. A meta-analysis of 9 randomised trials in colorectal cancer (1,198 patients, Frontiers in Nutrition, 2026) confirms the reduction in infections (OR 0.48; 0.34–0.66) but does NOT confirm an effect on anastomotic leak, postoperative ileus or length of stay — precisely the endpoints where the umbrella review sees benefit. We resolve this in favour of the more cautious reading, on two methodological grounds. First, an umbrella review pools meta-analyses that partly rest on the same primary trials, so a single result can be counted several times. Second, its length-of-stay estimate has heterogeneity of I² = 90.3%, meaning the individual studies disagree strongly and the averaged figure is unstable. One effect is reproducible across both sources: fewer infectious complications.

WHAT THESE RESULTS DO NOT SAY

They do not say that an immunonutrition formula replaces ordinary food, or that it improves cancer prognosis in itself — the endpoints measured concern the perioperative course, not cure of the tumour. Nor do they establish when to start: the observation that postoperative administration outperforms preoperative administration comes from a subgroup analysis and is therefore a hypothesis, not a finding. Finally, they say nothing about people who are not undergoing surgery.

SAFETY AND INTERACTIONS

Immunonutrition is a medical product used under hospital care, not a supplement bought independently; its composition (notably high arginine doses) has been questioned in patients with sepsis and severe organ failure. After gastrointestinal surgery, the route of delivery (oral, nasoenteric tube, jejunostomy) and the rate of volume escalation are part of the surgical plan. Whether, when and in what form nutritional support is introduced is decided by the treating team — the surgeon together with a clinical dietitian.